Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Direct conversion of human fibroblasts to multilineage blood progenitors

ABSTRACT: Similar to embryo-derived stem cells, application of human induced pluripotent stem cells (iPSCs) is limited by our understanding of lineage specification. Here, we demonstrate the ability to generate progenitors and mature cells of the hematopoietic fate directly from human dermal fibroblasts without establishing pluripotency. POU domain activation of hematopoietic transcription factors by ectopic expression of Oct-4, together with specific cytokine treatment, allowed generation of cells expressing the pan-leukocyte marker CD45. These unique fibroblast-derived cells gave rise to granulocytic, monocytic, megakaryocytic, and erythroid lineages, and demonstrated in vivo engraftment capacity. Distinct from PSC-derived hematopoietic cells, adult and not embryonic hematopoietic programs are activated, consistent with bypassing pluripotent state to generate blood fate. These findings suggest an alternative approach to cellular reprogramming for autologous cell-replacement therapies that avoids complications associated with the use of human PSCs.

ORGANISM(S): Homo sapiens

PROVIDER: GSE24621 | GEO | 2010/10/20

SECONDARY ACCESSION(S): PRJNA132443

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Direct conversion of human fibroblasts to multilineage blood progenitors

Project description:Similar to embryo-derived stem cells, application of human induced pluripotent stem cells (iPSCs) is limited by our understanding of lineage specification. Here, we demonstrate the ability to generate progenitors and mature cells of the hematopoietic fate directly from human dermal fibroblasts without establishing pluripotency. POU domain activation of hematopoietic transcription factors by ectopic expression of Oct-4, together with specific cytokine treatment, allowed generation of cells expressing the pan-leukocyte marker CD45. These unique fibroblast-derived cells gave rise to granulocytic, monocytic, megakaryocytic, and erythroid lineages, and demonstrated in vivo engraftment capacity. Distinct from PSC-derived hematopoietic cells, adult and not embryonic hematopoietic programs are activated, consistent with bypassing pluripotent state to generate blood fate. These findings suggest an alternative approach to cellular reprogramming for autologous cell-replacement therapies that avoids complications associated with the use of human PSCs. Molecular analysis was done on purified untransduced Fibs, Oct-4 transduced Fibs at day 4, CD45+ve Fibs at day 21 and hematopoietic cytokine treated CD45+ve Fibs at day 37. The day 4 Oct-4 transduced Fibs were isolated by puromycin selection overnight (Oct-4 vector contains puromycin resistance cassette), purity of sample was validated by staining for Oct-4 followed by Oct-4 expression analysis using flow cytometry; samples used for molecular analysis exhibited 99% Oct-4 levels. The day 21 and day 37 CD45+veFibsOct-4 were isolated based on their CD45 expression. D21 and D37 cells were stained with CD45-APC antibody (BD Biosciences) and sorted using FACSAria II (Becton- Dickinson); samples used for molecular analysis exhibited 99% CD45 levels. Analysis was performed on two biological replicates per sample.

2010-10-20 | E-GEOD-24621 | biostudies-arrayexpress

Loss of RUNX1 favors mesenchymal stem cells development at the expense of hematopoiesis in hPSC-derived hematopoiesis

Project description:Our data demonstrated an unprecedented role of RUNX1 in regulating hematopoietic and mesenchymal fate decisions in human pluripotent stem cells (hPSC)-derived hematopoiesis

2024-05-17 | GSE232147 | GEO

Engraftable multilineage hematopoietic cells differentiated from induced human pluripotent stem cells

Project description:Engraftable multilineage hematopoietic cells differentiated from induced human pluripotent stem cells

| PRJNA973621 | ENA

An engineered Sox17 induces somatic to neural stem cell fate transition independently from pluripotency reprogramming [ATAC-Seq]

Project description:Advances in molecular strategies to reprogram cell fate is a promising avenue for cell-based therapies. Methods to generate induced neural stem cells (iNSCs) are often slow with limited reprogramming events and it is unclear whether cells transit via a pluripotent state. We report an iNSC reprogramming approach from embryonic and aged mouse fibroblasts using an engineered Sox17 (eSox17FNV). eSox17FNV efficiently drives iNSC reprogramming while Sox2 or Sox17 fails to do so. eSox17FNV acquires the capacity to bind new protein partners to scan the genome more efficiently and possesses a more potent transactivation domain than Sox2. At the onset of reprogramming, in the presence of eSox17FNV, fibroblasts divert from a iPSC route towards iNSC fate. Further, lineage tracing shows that emerging iNSCs do not transit through a pluripotent state if POU factors are excluded. This reveals new molecular and physiological framework for iNSC generation and contrasts with lineage from pluripotency reprogramming.

2023-07-19 | GSE195554 | GEO

An engineered Sox17 induces somatic to neural stem cell fate transition independently from pluripotency reprogramming [RNA-seq]

2023-07-19 | GSE195551 | GEO

An engineered Sox17 induces somatic to neural stem cell fate transition independently from pluripotency reprogramming [RNA-seq II]

2023-07-19 | GSE225829 | GEO

An engineered Sox17 induces somatic to neural stem cell fate transition independently from pluripotency reprogramming [scRNA-seq]

2023-07-19 | GSE225306 | GEO

An engineered Sox17 induces somatic to neural stem cell fate transition independently from pluripotency reprogramming [RRBS]

2023-07-19 | GSE225305 | GEO

An engineered Sox17 induces somatic to neural stem cell fate transition independently from pluripotency reprogramming [RNA-seq III]

2023-07-19 | GSE225830 | GEO

Engraftable multilineage hematopoietic cells differentiated from induced human pluripotent stem cells

Project description:The production of hematopoietic stem cells (HSCs) from induced pluripotent stem cells (iPSCs) would have significant implications for medicine and biotechnology. We differentiated iPSCs to blood cells resembling the first repopulating HSCs of the human embryo. In immune deficient mice transplanted with iPSC-derived CD34+ cells, long term, low level bone marrow engraftment was seen in most animals. Although many animals were engrafted by myeloid, or myeloid and B lymphoid restricted progeny, 18% of mice receiving cells exposed to retinoids at day 3 of differentiation developed multilineage erythroid, myeloid and lymphoid cell engraftment (MLE), reflecting in vitro generation of HSCs or MPPs (termed iPSC-derived (i)HSCs). In a second cohort of mice, we observed in 36% of animals transplanted with cells receiving retinoids throughout differentiation. These studies identify conditions that yield engrafting iHSCs differentiated from human iPSCs and provide a foundation for the generation of cells for clinical translation.

2024-08-03 | GSE232710 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data